Related Experiment Video
Updated: Aug 1, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Discovering potential inhibitors of Raf proto-oncogene serine/threonine kinase 1: a virtual screening approach
Afsha Khan1, Mohamed Ahmed Bealy2, Bandar Alharbi3
1Department of Computer Science, Jamia Millia Islamia, New Delhi, India.
Abstract:
Raf proto-oncogene serine/threonine kinase 1 (RAF1 or c-Raf) is a serine/threonine protein kinase crucial in regulating cell growth, differentiation, and survival. Any disruption or overexpression of RAF1 can result in neoplastic transformation and other disorders such as cardiomyopathy, Noonan syndrome, leopard syndrome, etc. RAF1 has been identified as a potential therapeutic target in drug development against various complex diseases, including cancer, due to its remarkable role in disease progression. Here, we carried out a multitier virtual screening study involving different in-silico approaches to discover potential inhibitors of RAF1. After applying the Lipinski rule of five, we retrieved all phytocompounds from the IMPPAT database based on their physicochemical properties. We performed a molecular docking-based virtual screening and got top hits with the best binding affinity and ligand efficiency. Then we screened out the selected hits using the PAINS filter, ADMET properties, and other druglike features. Eventually, PASS evaluation identifies two phytocompounds, Moracin C and Tectochrysin, with appreciable anti-cancerous properties. Finally, all-atom molecular dynamics simulation (MDS) followed by interaction analysis was performed on the elucidated compounds in complex with RAF1 for 200 ns to investigate their time-evolution dynamics and interaction mechanism. Molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) and Dynamical Cross-Correlation Matrix (DCCM) analyses then followed these results from the simulated trajectories. According to the results, the elucidated compounds stabilize the RAF1 structure and lead to fewer conformational alterations. The results of the current study indicated that Moracin C and Tectochrysin could serve as potential inhibitors of RAF1 after required validation.Communicated by Ramaswamy H. Sarma.
Insights
Researchers identified Moracin C and Tectochrysin as potential RAF1 inhibitors using computational methods. These natural compounds show promise for developing new anti-cancer drugs by stabilizing the RAF1 protein structure.
Area of Science:
- Biochemistry
- Computational Biology
- Pharmacology
Background:
- Raf proto-oncogene serine/threonine kinase 1 (RAF1) is vital for cell regulation, and its dysregulation is linked to cancers and other diseases.
- RAF1 is a significant therapeutic target for developing novel anti-cancer drugs.
- Identifying effective RAF1 inhibitors is crucial for advancing cancer treatment strategies.
Purpose of the Study:
- To discover potential phytocompound inhibitors of RAF1 using a multitier virtual screening approach.
- To evaluate the drug-likeness and binding efficacy of identified compounds against RAF1.
- To investigate the molecular dynamics and interaction mechanisms of promising inhibitors with RAF1.
Main Methods:
- Phytocompound retrieval from the IMPPAT database based on Lipinski's rule of five.
- Molecular docking and virtual screening to identify compounds with high binding affinity.
- PAINS filtering, ADMET property prediction, and PASS evaluation for drug-likeness.
- All-atom molecular dynamics simulations (200 ns), MM-PBSA, and DCCM analysis.
Main Results:
- Moracin C and Tectochrysin were identified as potential RAF1 inhibitors with favorable binding affinities.
- These compounds demonstrated good drug-like properties and passed various filtering criteria.
- Molecular dynamics simulations confirmed that Moracin C and Tectochrysin stabilize the RAF1 structure, reducing conformational changes.
Conclusions:
- Moracin C and Tectochrysin show significant potential as novel anti-cancer agents targeting RAF1.
- The identified compounds could serve as lead molecules for further drug development against RAF1-associated diseases.
- Computational approaches are effective in discovering natural product-based inhibitors for therapeutic targets like RAF1.
Related Concept Videos
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Ras Gene
Ras is a...
MAPK Signaling Cascades

